TNNT2 and COVID-19: In particular, Sandoval et al. [6] stated that the assay of specific cardiac biomarkers (especially hs-cTnI and hs-cTnT) in serial samples collected from patients admitted to the ED and hospitalized for COVID-19 facilitates risk stratification, helps decide when to use cardiac imaging, and indicates stage categorization and disease phenotyping among patients.